Literature DB >> 7469518

Prognosis and management of polymyalgia rheumatica.

J G Jones, B L Hazleman.   

Abstract

Polymyalgia rheumatica (PMR) is considered to be a benign disease by some, while others think it is a more serious illness which required similar treatment to giant cell arteritis (GCA). The progress of 85 patients with PMR who presented to a district general hospital has been studied in an attempt to study this relationship. Thirty-eight patients had PMR alone, and 14 developed PMR and GCA within 1 month. Five patients presented with GCA and then developed PMR, and 28 patients developed symptoms of GCA after presenting with PMR (PMR leads to GCA). Arteritis and complications developed up to 9 years after the onset of PMR (mean 1 year). Twenty-two patients (26%) developed some cerebral or visual complication. Fifteen of these patients were in the PMR leads to GCA group. All 6 patients with permanent loss of vision were in this group. Seven patients developed complications while on corticosteroids. 97% of patients required corticosteroids for at least 1 year; 32% of patients still required 10 mg of prednisone or more after 1 year. PMR is not a benign disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7469518      PMCID: PMC1000646          DOI: 10.1136/ard.40.1.1

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Neurologic aspects of temporal arteritis.

Authors:  R W HOLLENHORST; J R BROWN; H P WAGENER; R M SHICK
Journal:  Neurology       Date:  1960-05       Impact factor: 9.910

2.  A prospective study of 102 patients with the polymyalgia rheumatica syndrome.

Authors:  E N Coomes; R M Ellis; A G Kay
Journal:  Rheumatol Rehabil       Date:  1976-11

Review 3.  Polymyalgia rheumatica and giant cell arteritis.

Authors:  R E Ettlinger; G G Hunder; L E Ward
Journal:  Annu Rev Med       Date:  1978       Impact factor: 13.739

4.  Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings.

Authors:  P Fauchald; O Rygvold; B Oystese
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

Review 5.  Giant cell arteritis: including temporal arteritis and polymyalgia rheumatica.

Authors:  C R Hamilton; W M Shelley; P A Tumulty
Journal:  Medicine (Baltimore)       Date:  1971-01       Impact factor: 1.889

6.  Manifestations of giant cell arteritis.

Authors:  L A Healey; K R Wilske
Journal:  Med Clin North Am       Date:  1977-03       Impact factor: 5.456

7.  Polymyalgia rheumatica and giant cell arteritis: a seven-year survey.

Authors:  A B Myles
Journal:  Rheumatol Rehabil       Date:  1975-11

8.  Giant cell arteritis. Clinical features and involvement of different organs.

Authors:  B E Malmvall; B A Bengtsson
Journal:  Scand J Rheumatol       Date:  1978       Impact factor: 3.641

9.  Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study.

Authors:  K A Huston; G G Hunder; J T Lie; R H Kennedy; L R Elveback
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

View more
  55 in total

1.  Giant Cell Arteritis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

Review 2.  Stopping steroids in polymyalgia rheumatica and giant cell arteritis.

Authors:  V Kyle; B L Hazelman
Journal:  BMJ       Date:  1990-02-10

3.  Isolation and analysis of immune complexes from sera of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  A J Smith; V Kyle; T E Cawston; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

4.  A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica.

Authors:  H A Bird; B F Leeb; C M Montecucco; N Misiuniene; G Nesher; S Pai; C Pease; J Rovensky; B Rozman
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

5.  Liver scan abnormalities in polymyalgia rheumatica/giant cell arteritis.

Authors:  V Kyle; E P Wraight; B L Hazleman
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

6.  A seasonal pattern in the onset of polymyalgia rheumatica.

Authors:  M A Cimmino; R Caporali; C M Montecucco; S Rovida; E Baratelli; M Broggini
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

Review 7.  Polymyalgia rheumatica.

Authors:  Clement J Michet; Eric L Matteson
Journal:  BMJ       Date:  2008-04-05

8.  Inflammation of the uveal tract as a presenting feature of temporal arteritis.

Authors:  B Dasgupta; C Pitzalis; G S Panayi
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

9.  Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study.

Authors:  R Caporali; C Montecucco; O Epis; F Bobbio-Pallavicini; T Maio; M A Cimmino
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 10.  Giant cell arteritis. Epidemiology and treatment.

Authors:  E Nordborg; R Andersson; B A Bengtsson
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.